The GLP‐1R agonist liraglutide has been shown to reduce bodyweight in patients with prediabetes and in those with obesity,104 and has been approved for weight management in adults with obesity as an adjunct to a reduced‐calorie diet and increased physical activity.65 Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.